Rationale: TAFRO syndrome is a systemic inflammatory disease proposed recently from Japan. The cause of TAFRO syndrome is unclear. Moreover, the disease characteristics and kidney pathology are yet unknown well and there are few cases. Herein, we report a patient with TAFRO syndrome and present the features of the renal histopathology.
Introduction
TAFRO syndrome (TS) is a systemic inflammatory disease of unknown aetiology, and published reports suggest that it might be related to Castleman disease (CD). [1] In 2010, Takai et al [2] reported 3 patients with megakaryocytosis, severe thrombocytopenia, mild myelofibrosis, high fever, pleural effusion, abdominal ascites, hepatosplenomegaly, and lymph node enlargement; and proposed the name TAFRO syndrome (TS), using the first letters of the symptoms that make up the characteristic clinical picture: thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, and organomegaly.
As there is a type of CD known as multicenteric Castleman disease (MCD) that often presents with generalized symptoms, TS frequently needs to be differentiated from MCD, and currently, investigation is underway to determine the characteristics of this disease. We encountered a patient with TS who presented with an anterior mediastinal tumor, associated by multiple lymph nodes enlargement, fever, anemia, proteinuria, and renal dysfunction.
Only a small number of reports have been published about the renal pathology in patients with TS. The renal pathology in many of these reports was membranoproliferative glomerulonephritis (MPGN), which is consistent with our case. On the other hand, amyloidosis, which is often seen in patients with MCD, was not a finding in these reports. Therefore, we postulate that renal pathology findings may assist in the diagnosis of TS.
Case presentation
A 55-year-old woman presented to our hospital with the main complaint of dyspnoea in December 2014. Mediastinal imaging showed pleural effusion and an anterior mediastinal mass. A CTguided biopsy was performed, but showed no significant findings. The patient then developed proteinuria, secondary exacerbation of pleural effusion and generalized oedema. In January 2015, the patient was hospitalized in our department with dyspnoea.
As this is a case study, ethics approval was not required. The patient received an explanation of the procedures and possible risks of this study and gave written informed consent along the policy of our ethical committee.
The past medical history was significant for hypertension and a renal stone. The patient smoked 20 cigarettes/day for approximately 35 years, but did not drink alcohol. Family history was unremarkable and she had no known drug allergies.
The patient's height was 151.4 cm, body weight was 81.6 kg, blood pressure was 164/82 mm Hg, heart rate was regular at 92/min, body temperature was 37.1°C, and oxygen saturation was 97% with oxygen administered via nasal cannula at a rate of 1 L/min.
She was conscious and lucid. Palpebral conjunctiva showed pallor. Neck palpation revealed a number of enlarged lymph nodes measuring 1 cm in diameter, which were painless with elastic consistency. No murmurs were auscultated on cardiac examination. Chest auscultation revealed bilaterally diminished breathing sounds in the lower lung fields. The abdomen was soft but distended, and not tender to palpation. Bowel sounds were enhanced. Shifting dullness was elicited.
Marked oedema was noted in both lower limbs. There was no joint pain, dermal, or neurological findings.
Clinical course during the first hospitalisation
Urinalysis showed proteinuria (Table 1) , and the blood tests revealed anemia, abnormal coagulation, hypoproteinemia, mild renal dysfunction, elevated alkaline phosphatase (ALP), elevated inflammatory markers, and elevated cardiac enzymes. The patient did not have hypergammaglobulinemia or hypocomplementemia, and the tumor marker soluble IL-2 receptor (sIL-2R) was elevated. The patient tested negative for various autoantibodies, human and Epstein-Barr virus (EBV) infections, so there were no diseasespecific findings. Interleukin-6 (IL-6) was mildly elevated. A CT scan of the chest and abdomen showed cardiomegaly, pleural effusion, abdominal ascites, severe subcutaneous oedema, a 65-Â 25-mm mass with internal heterogeneity in the anterior mediastinum and multiple enlarged lymph nodes in the neck, both axillae, mediastinum, and groin ( Fig. 1 ). An 18 FDG-positron emission tomography (PET) scan showed multiple enlarged lymph nodes in both sides of the neck, in the supraclavicular fossa, axilla, mediastinum, and from the right common iliac to the external iliac artery (maximum diameter of approximately 20 mm, with multiple different sizes), with abnormal FDG uptake (Fig. 2) . Initially, we suspected nephrotic syndrome secondary to a malignant mediastinal tumor, based on the findings of the anterior mediastinal tumor, multiple enlarged lymph nodes, and anemia. Renal biopsy was considered risky at that time; therefore, large doses of different diuretics (furosemide 500 mg, trichlormethiazide 8 mg, tolvaptan 15 mg, eplerenone 50 mg) were administered to control the pleural effusion. In late January 2015, resection of the anterior mediastinal tumor was performed. Gross examination of the resected anterior mediastinal tumor showed lesions with multinodular fibrosis (Fig. 3) , and histological examination showed hyperplasic lymphoid follicles and lymphocytes concentrically arranged in the mantle layer. Vascular proliferation with hyalinization was seen in the germinal centre, which was consistent with the features of hyaline vascular (HV)-type CD (Fig. 4) .
Based on the CT and PET scan findings, there were multiple enlarged cervical lymph nodes, which showed the same histological findings as the resected tumor. At this time, the patient was diagnosed with MCD based on the clinical picture of multiple enlarged lymph nodes, fever, anemia, renal dysfunction, and oedema.
After resection of the lesion in January 2015, the patient's response to the diuretics improved significantly, and her body weight decreased form 81.6 kg at admission to 55 kg. The oedema, respiratory, and renal functions all rapidly improved and the patient was discharged. However, the enlarged lymph nodes persisted, so the patient was closely monitored in anticipation of recurrence.
Clinical course during second hospitalisation
In July 2015, the patient's creatinine (Cr) was 0.69 mg/dL, and proteinuria was negative. One month later, in August 2015, the patient developed proteinuria (536 mg/gCr), renal failure (Cr 2.1 mg/dL, estimated glomerular filtration rate [eGFR] 20 mL/min/ 1.73 m 2 ), generalized anasarca, anemia (hemoglobin 5.9 g/dL), and thrombocytopenia (platelet count 6.9 Â 10 4 /ml). sIL-2R, platelet-associated IgG (PaIgG), IL-6, and vascular endothelial growth factor (VEGF) were all elevated ( Table 2 ). The patient was readmitted for further enlargement of the residual lymph nodes and development of hepatosplenomegaly. A bone marrow biopsy showed increased megakaryocytes and mild myelofibrosis ( Fig. 5 ), so the patient was diagnosed with TAFRO syndrome. The patient responded to pulse steroid therapy, followed by 60 mg/day oral prednisolone (PSL), and the steroid dose was reduced as the symptoms improved (Fig. 6) .
In January 2016, during which the patient was receiving 10 mg/ day PSL, a renal biopsy was performed to unveil the renal pathology. Light microscopy ( Fig. 7) revealed hyalinization of 1/ 11 glomeruli, diffuse and global mesangial proliferation, and glomerular lobulation with partial duplication of the basement membrane. Stromal fibrosis with patchy tubular atrophy was noted, together with peripheral lymphocytic infiltration. Direct fast scarlet staining was negative, and there was no amyloid deposition. Immunofluorescence was positive for IgM, which was partially granular, and negative for IgG, IgA, fibrinogen, C3, C4, and C1q. Electron microscopy revealed no electron dense deposits with partial disappearance of the podocyte foot processes. There was partial duplication of the basement membrane and mesangial interposition, which were consistent with MPGN-like findings. The patient's subsequent clinical progress was favourable, and remission was maintained with oral steroid therapy (PSL 3 mg/day).
Discussion and conclusions
CD is a rare lymphoproliferative disorder first reported in 1956 by Castleman et al [3] as thymoma-like mediastinal lymph node enlargement. After the first report, many other similar cases were reported, and the disease was classified into a number of different com types. [4, 5] CD is classified according to the histopathological findings into HV type, plasma cell (PC) type, and mixed type. Clinically, the disease is classified as unicenteric Castleman disease (UCD), where the enlarged lymph nodes are localized; and MCD, where the enlarged lymph nodes are generalized. Many of the patients with UCD have the HV type with asymptomatic mediastinal lymph node enlargement; however, a rarity may have associated clinical symptoms. If the entire mass is resected, the prognosis is good, and reports show that resection of the lesion can improve the condition, as it is associated with reduction in IL-6. [6] On the other hand, MCD is usually of the PC or mixed type, this condition often recurs and the prognosis is poor.
In terms of the cause of MCD, in Europe and the United States it is known to be a disease that develops in conjunction with infections such as HIV and HHV-8, but in Japan, almost all the reported cases with MCD test negative for HIV and HHV-8, so it is presumed that the pathology of MCD in Japan may differ from that in Europe and the U.S. MCD is often associated with systemic symptoms including fever, malaise, C-reactive protein (CRP) elevation, serum amyloid A (SAA) elevation, anemia, polyclonal gammopathy, liver damage, and renal dysfunction. The kidney damage associated with MCD ranges from minor renal function test abnormalities with only hematuria and/or proteinuria, to serious conditions including nephritis, nephrotic syndrome, acute renal failure, and chronic renal failure, necessitating hemodialysis. [7] The cause is reported to involve the production of IL-6 from lymph nodes. [8] IL-6 is thought to cause amyloid deposition through increasing the AA amyloid precursor SAA protein, which accumulates in hepatocytes, [9] and cause an increase in proliferation of renal mesangial cells [10] and hyperviscosity syndrome associated with gammopathy. [11] [12] [13] A number of reports examined multiple cases with renal tissue lesions in France [8] and China. [7, 14] Yuan et al [14] examined 49 cases with MCD; the renal histology was thrombotic microangiopathy (n = 12), amyloidosis (n = 9), MPGN (n = 7), and other (n = 21). Xu et al [7] examined CD, combining MCD and UCD, to investigate the renal histological types in a total of 94 patients, comprised of 64 cases reported to date, 11 of their own cases and 19 cases reported by El Karoui et al. [8] The reported histological types were diverse and included amyloidosis (n = 29), small vessel lesion with MPGN and thrombotic microangiopathy (n = 27), interstitial nephritis (n = 7), mesangioproliferative glomerulonephritis (n = 5), crescentic glomerulonephritis (n = 5), focal segmental glomerulosclerosis (n = 4), membranous nephropathy (n = 4), minimal change disease (n = 3), and other (n = 11), with amyloidosis being the most common. [7] The histopathology of the lymph nodes in our case was consistent with HV-type CD, and the condition was initially diagnosed as MCD based on the clinical picture of multiple enlarged lymph nodes, fever, anemia, renal dysfunction, and oedema. The patient also presented with generalized anasarca, proteinuria, and renal failure, but these symptoms improved after resection of the lesion. Moreover, IL-6 and VEGF levels decreased with reduction in the size of the lesion. Therefore, we postulated that the increased vascular permeability improved. In general, HV-type CD is often unicenteric, and we considered the complication of systemic symptoms with multiple enlarged lymph nodes to be atypical. Furthermore, enlarged lymph nodes other than the resected mass persisted after surgery, and generalized anasarca, proteinuria, and renal failure recurred approximately 6 months after resection, which was also associated with thrombocytopenia. Therefore, we considered that our case represent a typical clinical picture of TS, with T: thrombocytopenia, A: anasarca, F: myelofibrosis, R: renal dysfunction, and O: organomegaly; consequently, the patient was treated with steroid therapy. This resulted in shrinkage of the generalized lymphadenopathy, improvement in renal function, resolution of proteinuria, and clinical improvement, including normalization of the levels of serum protein and albumin.
The background of establishing the disease concept of TS is as follows: In 2008, Kojima et al [15] reported cases with MCD-like pathology, which lacked IPL (idiopathic plasmacytic lymphadenopathy)-like gammopathy. Lymph node biopsies were consistent with the HV type rather than the PC type, and there were high rates of pleural effusion, ascites, and thrombocytopenia, so these cases were diagnosed as non-IPL. [15] Then in 2010, Takai et al [2] reported cases with TS, and in 2013, Kawabata et al [16] reported 3 out of 21 MCD cases that had TS-like symptoms. There were many similarities in the cases described in these three reports, [2, 16] and in 2013 a new systemic inflammatory disease was jointly proposed and announced as Castleman-Kojima disease/TAFRO syndrome. [17] TS is a disease concept that was recently proposed in Japan, and much of the lymph node pathologies are consistent with mixed type, [18] but there are also a number of reports with pathology findings consistent with HV type. [19, 20] This condition is more commonly reported in Japan than overseas, with a few reports from India, [21] Italy, [22, 23] and France, [24] which might be explained by the unawareness of this disease overseas.
In 2015, Masaki et al [1] examined 28 cases with TS, and updated the diagnostic criteria (Table 3 ). In these diagnostic criteria, they established three major categories: anasarca, thrombocytopenia, and systemic inflammation, and 4 minor categories: CD-like features on lymph node biopsy, reticulin myelofibrosis and/or increased number of megakaryocytes in bone marrow, mild organomegaly, and progressive renal insufficiency. Patients that meet 3 of the major categories and 2 of the minor categories may be diagnosed as TS. Our case was diagnosed with TS based on these diagnostic criteria. Our case developed thrombocytopenia approximately 8 months after onset, so this case progressed slowly.
A comparison of the characteristics of this case and TS cases from multiple facilities in Japan is shown in Table 4 . [18] TS is common in middle-aged women, and the characteristic clinical data include generalized anasarca, fever, inflammation, thrombocytopenia, anemia (normo-to microcytic), ALP elevation, low level of lactate dehydrogenase, and renal dysfunction, and often a bone marrow puncture will yield a dry tap with myelofibrosis and increased megakaryocytes. Clinically, patients present with hepatosplenomegaly. Multiple enlarged lymph nodes are also seen, but are commonly only mildly enlarged measuring 1.5 cm or smaller, and there is also mild elevation of polyclonal gamma globulins. Other characteristics are elevated IL-6, VEGF, and sIL-2R; negativity for HHV-8, EBV, and HIV; uptake seen on PET scans, and occasionally a case might be positive for auto-antibodies, but without satisfying the diagnostic criteria of autoimmune diseases or other diseases, [25] and many cases are acute or subacute. [26] In TS thrombocytopenia, Pa-IgG (platelet associated immunoglobulin G) is often elevated, [25] so it is suspected that there is some sort of immune mechanism at work. [20, 27] There are some cases of TS with poor prognoses, so it is important to intervene with treatment early, [1] and TS usually responds well to steroids, cyclosporin (CyA), the anti-IL-6 receptor antibodies tocilizumab, and rituximab. [20, 28, 29] Furuto et al. Medicine (2018) 
Recently there have been reports that pathologically differentiate TS from the conventional PC type MCD, as lymph node biopsies in TS revealed atrophic germinal centres with enlarged nuclei of endothelial cells and proliferation of endothelial venules in the interfollicular zone (Table 5) . [30] Other reports showed that some cases with TS were difficult to treat with tocilizumab but responded well to CyA, suggesting the involvement of IL-2 as well as IL-6 in TS. [28] Therefore, TS should be thought of as an independent disease, as it differs from MCD.
TS are also thought to have a different aetiology from MCD based on renal histology. The renal histologies in 9 patients with TS in Japan, including our case, are shown in Table 6 . [26, [31] [32] [33] [34] [35] [36] The most common finding was MPGN-like histology, and there were no reports of amyloidosis. MPGN-like findings were significantly common in TS when considering these 9 cases of TS, and when considering the renal pathology reports of the aforementioned 49 cases of MCD examined by Yuan et al. [14] As mentioned above, IL-6 is considered to be one of the causes of Table 3 Diagnostic criteria of TAFRO syndrome (2015) . A diagnosis of TAFRO syndrome requires all of the three major categories and at least two of four minor categories As it is very important to exclude malignancies, including lymphoma, lymph node biopsy, if applicable, is strongly recommended A. Major categories (1) Anasarca, including pleural effusion, ascites and general edema (2) Thrombocytopenia; defined as a pretreatment platelet count 100,000/ml (3) Systemic inflammation, defined as fever of unknown etiology above 37.5°C and/or serum C-reactive protein concentration ≥2 mg/dL B. Minor categories (1) Castleman's disease-like features on lymph node biopsy (2) Reticulin myelofibrosis and/or increased number of megakaryocytes in bone marrow (3) Mild organomegaly, including hepatomegaly, splenomegaly and lymphadenopathy (4) Progressive renal insufficiency C. Diseases to be excluded (1) Malignancies, including lymphoma, myeloma, mesothelioma, et cetera (2) Autoimmune disorders, including systemic lupus erythematosus (SLE), ANCA-associated vasculitis, etc. [19] and other reports where the levels were not necessarily high, [1, 26, 31] suggesting that the low incidence of renal amyloidosis may be related to TS. In fact, in our case also, IL-6 was not markedly elevated. The aetiology of TS is still unknown, [1] so it is important to study more cases of TS and analyze the renal pathology profile.
In conclusion, we encountered a case that we initially diagnosed as HV type MCD, but the patient developed thrombocytopenia in the course of the disease and ultimately the condition was diagnosed as TS. The renal histopathological profile of TS presents with MPGN-like findings, and when comparing our case to previous reports, it was found that MPGN-like findings were found in many patients with TS. Our case reiterated the importance of careful monitoring of patients as the characteristic TS findings might present over the course of time. Table 6 Renal histology reports of TS cases in Japan.
Age Sex
Urinalysis findings, renal function Renal histology findings Treatment 2015 Hamada et al [25] 77 F [36] 49 F renal Renal dysfunction
Mesangioproliferative glomerulonephritis
Responded well to steroids/CyA 2015 Fujita [36] 65 F Proteinuria Minor abnormality with minimal immune complex deposition 
